Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Aleksandra Eyring"'
Autor:
Nickolas Papadopoulos, Nianqing Xiao, Robert A. Anders, Kristen K. Ciombor, Shibin Zhou, Katherine M. Bever, Cara Wilt, Bao H. Lam, Hao Wang, Janis M. Taube, George A. Fisher, Matthias Holdhoff, Fay Wong, Richard M. Goldberg, Amanda N. Fader, Ludmila Danilova, Jennifer N. Durham, Laveet K. Aulakh, David Spetzler, Leslie Cope, Dung T. Le, Christian F. Meyer, Franck Housseau, James J. Lee, Aleksandra Eyring, Andrew K. Joe, James R. Eshleman, Deborah K. Armstrong, Bjarne Bartlett, Kellie N. Smith, Brandon Luber, Agnieszka A. Rucki, Daniel A. Laheru, Steve Lu, Nilofer S. Azad, Todd S. Crocenzi, Kenneth W. Kinzler, Tim F. Greten, Austin G. Duffy, Bert Vogelstein, Drew M. Pardoll, Luis A. Diaz, Atif Zaheer, Holly Kemberling, S. Peter Kang, Ross C. Donehower
Predicting responses to immunotherapy Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have favorable responses to PD-1 blockade immunotherapy. In a phase 2 clinical trial, Le et al. showed that treatment success is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4527179e77e9a993495411588f44d3
https://europepmc.org/articles/PMC5576142/
https://europepmc.org/articles/PMC5576142/
Autor:
Jennifer N. Uram, Edward J. Tanner, Tim F. Greten, George A. Fisher, Dung T. Le, D. K. Armstrong, Amanda N. Fader, Luis A. Diaz, Aleksandra Eyring, Hao Wang
Publikováno v:
Gynecologic Oncology. 141:206-207
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb6131243c00c9a3fe388aa249bbd9fb
https://doi.org/10.1016/j.ygyno.2016.04.532
https://doi.org/10.1016/j.ygyno.2016.04.532
Autor:
Daniel A. Laheru, Dung T. Le, Todd S. Crocenzi, Jennifer N. Uram, Luis A. Diaz, Tim F. Greten, Richard M. Goldberg, Soonmo Peter Kang, Bjarne Bartlett, Bert Vogelstein, James R. Eshleman, Holly Kemberling, James J. Lee, George A. Fisher, Aleksandra Eyring, Hao Wang, Ross C. Donehower, Minori Koshiji, Nilofer S. Azad, Robert A. Anders
Publikováno v:
Journal of Clinical Oncology. 34:103-103
103Background: Mismatch repair deficient (dMMR) colon cancers are densely infiltrated with CD8+T cells and regress when treated with anti-programmed death-1 (PD-1) antibodies. This anti-tumor response is thought to be potentiated by the thousands of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e4167f3c574f7f752ba9009d5835dd8
https://doi.org/10.1200/jco.2016.34.15_suppl.103
https://doi.org/10.1200/jco.2016.34.15_suppl.103
Autor:
Tim F. Greten, Bert Vogelstein, Bjarne Bartlett, Tianna Dauses, Jennifer N. Uram, Daniel A. Laheru, James J. Lee, Christian F. Meyer, Nilofer S. Azad, Todd S. Crocenzi, George A. Fisher, Hao Wang, Deborah K. Armstrong, Amanda N. Fader, Luis A. Diaz, Dung T. Le, Minori Koshiji, Richard M. Goldberg, Aleksandra Eyring, Holly Kemberling
Publikováno v:
Journal of Clinical Oncology. 34:3003-3003
3003Background: Mismatch repair deficiency (MRD) is feature of many cancers at a frequency of approximately 1 in 30 patients independent of tumor histology. Tumors with MRD are deficient in the repair of specific DNA replication errors and as a resul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5badc598bcfd6a692e30954a1113dfc4
https://doi.org/10.1200/jco.2016.34.15_suppl.3003
https://doi.org/10.1200/jco.2016.34.15_suppl.3003
Autor:
Brandon Luber, Daniel A. Laheru, Todd S. Crocenzi, Nilofer S. Azad, Richard M. Goldberg, Tim F. Greten, Bjarne Bartlett, Aleksandra Eyring, James J. Lee, Bert Vogelstein, Holly Kemberling, James R. Eshleman, Luis A. Diaz, George A. Fisher, Dung T. Le, Hao Wang, Ross C. Donehower, Robert A. Anders, Minori Koshiji, Jennifer N. Uram
Publikováno v:
Journal of Clinical Oncology. 34:195-195
195 Background: Mismatch repair (MMR) deficient tumors harbor hundreds to thousands of mutations that may produce neoantigens that can be recognized and targeted by T cells. We have shown that MMR deficiency can serve as a predictive biomarker for se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66b3568fc7875eb4b284ed25fc75444c
https://doi.org/10.1200/jco.2016.34.4_suppl.195
https://doi.org/10.1200/jco.2016.34.4_suppl.195
Autor:
Steve M Duffy, Hao Wang, Holly Kemberling, Bjarne Bartlett, Nilofer S. Azad, Dung T. Le, Robert A. Anders, George A. Fisher, Andrew D. Skora, Ross C. Donehower, Brandon Luber, Daniel A. Laheru, Bert Vogelstein, Todd S. Crocenzi, Jennifer N. Uram, Luis A. Diaz, Aleksandra Eyring, Minori Koshiji, James R. Eshleman, James J. Lee
Publikováno v:
Journal of Clinical Oncology. 33:LBA100-LBA100
LBA100 Background: Somatic mutations have the potential to be recognized as “non-self” immunogenic antigens. Tumors with genetic defects in mismatch repair (MMR) harbor many more mutations than tumors of the same type without such repair defects.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64d0677a11ee5fceb6aea6e0bb072007
https://doi.org/10.1200/jco.2015.33.15_suppl.lba100
https://doi.org/10.1200/jco.2015.33.15_suppl.lba100